Determination of key parameters for a mechanism-based model to predict doxorubicin release from actively loaded liposomes

Journal of Pharmaceutical Sciences

Volumn 104, Issue 3, 2015, Pages 1087-1098

  Csuhai, Eva ^a   Kangarlou, Sogol ^b   Xiang, Tian Xiang ^b   Ponta, Andrei ^b   Bummer, Paul ^b   Choi, Duhyung ^b   Anderson, Bradley D ^b  

^a TRANSYLVANIA UNIVERSITY   (United States)

^b University of Kentucky   (United States)

Author keywords

Biophysical models; Cancer chemotherapy; Controlled release; Dissolution; Drug delivery systems; In vitro models; Liposomes; Nanoparticles; Permeability; Transport

Indexed keywords

DOXORUBICIN; LIPOSOME; ANTINEOPLASTIC ANTIBIOTIC; LIPID; MACROGOL DERIVATIVE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; ENCAPSULATION; GEL FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOME MEMBRANE; MEMBRANE PERMEABILITY; SUSPENSION; TEMPERATURE DEPENDENCE; ANALOGS AND DERIVATIVES; CHEMICAL MODEL; CHEMISTRY; DRUG STABILITY; KINETICS; MEDICINAL CHEMISTRY; PERMEABILITY; PH; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

ANTIBIOTICS, ANTINEOPLASTIC; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; KINETICS; LIPIDS; LIPOSOMES; MODELS, CHEMICAL; PERMEABILITY; POLYETHYLENE GLYCOLS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84922784884     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24307     Document Type: Article

References (71)

1. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992.
2. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54 (5) : 631-651.
3. Marchesan S, Prato M. 2013. Nanomaterials for (nano) medicine. ACS Med Chem Lett 4 (2) : 147-149.
4. McCarron PA, Hall M. 2004. Pharmaceutical nanotechnology. Encycl Nanosci Nanotechnol 8: 469-487.
5. Mei L, Zhang Z, Zhao L, Huang L, Yang XL, Tang J, Feng SS. 2013. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev 65 (6) : 880-890.
6. Musacchio T, Torchilin VP. 2011. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci (Landmark Ed) 16 (4) : 1388-1412.
7. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. 2008. Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 83 (5) : 761-769.
8. Maeda H, Nakamura H, Fang J. 2013. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65: 71-79.
9. Arias JL. 2011. Drug targeting strategies in cancer treatment: An overview. Mini-Rev Med Chem 11 (1) : 1-17.
10. Torchilin V. 2011. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63 (3) : 131-135.
11. Barenholz Y. 2012. Doxil-The first FDA-Approved nano-drug: From an idea to a product. Handbook of harnessing biomaterials in nanomedicine. Singapore: Pan Stanford Publishing, pp 335-398.
12. Byrne JD, Betancourt T, Brannon-Peppas L. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60 (15) : 1615-1626.
13. Fenske DB, Cullis PR. 2008. Liposomal nanomedicines. Expert Opin Drug Deliv 5 (1) : 25-44.
14. Maurer N, Fenske DB, Cullis PR. 2001. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 1 (6) : 923-947.
15. Loew S, Fahr A, May S. 2011. Modeling the release kinetics of poorly water-soluble drug molecules from liposomal nanocarriers. J Drug Deliv 2011: 376548, 10 pages.
16. Zeng L, An L, Wu X. 2011. Modeling drug-carrier interaction in the drug release from nanocarriers. J Drug Deliv 2011: 307038, 15 pages.
17. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. 2006. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66 (6) : 3271-3277.
18. Joguparthi V, Anderson BD. 2008. Liposomal delivery of hydrophobic weak acids: Enhancement of drug retention using a high intraliposomal pH. J Pharm Sci 97 (1) : 433-454.
19. Johnston MJW, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D, Cullis PR. 2006. Therapeutically optimized rates of drug release can be achieved by varying the drug-Tolipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 1758: 55-64.
20. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. 2008. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 97: 4696-4740.
21. Chang HI, Yeh MK. 2012. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int J Nanomed 7: 49-60.
22. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, Cennamo G, Rotundo MS, Tagliaferri P, Caraglia M, Del Prete S. 2008. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly womenor=65 years of age. Cancer Chemother Pharmacol 62 (2) : 285-292.
23. Barenholz Y. 2012. Doxil (R) -The first FDA-Approved nano-drug: Lessons learned. J Control Release 160 (2) : 117-134.
24. Jiang W, Lionberger R, Yu LX. 2011. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3 (3) : 333-344.
25. Ishida O, Maruyama K, Sasaki K, Iwatsuru M. 1999. Sizedependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm 190 (1) : 49-56.
26. Joguparthi V, Anderson BD. 2008. Effect of cyclodextrin complexation on the liposome permeability of a model hydrophobic weak acid. Pharm Res 25 (11) : 2505-2515.
27. Joguparthi V, Feng S, Anderson BD. 2008. Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67. Int J Pharm 352 (1-2) : 17-28.
28. Joguparthi V, Xiang TX, Anderson BD. 2008. Liposome transport of hydrophobic drugs: Gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67. J Pharm Sci 97 (1) : 400-420.
29. Tejwani RW, Stouch TR, Anderson BD. 2009. Substituent effects on the ionization and partitioning of p-(aminoethyl) phenols and structurally related compounds: Electrostatic effects dependent on conformation. J Pharm Sci 98 (12) : 4534-4544.
30. Fugit KD, Anderson BD. 2014. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan. J Control Release 174: 88-97.
31. Xiang TX, Xu YH, Anderson BD. 1998. The barrier domain for solute permeation varies with lipid bilayer phase structure. J Membr Biol 165 (1) : 77-90.
32. Xiang T-X, Jiang Z-Q, Song L, Anderson BD. 2006. Molecular dynamics simulations and experimental studies of binding and mobility of 7-T-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) and its 20 (S) -4-Aminobutyrate ester in DMPC membranes. Mol Pharm 3: 589-600.
33. Modi S, Anderson BD. 2013. Bilayer composition, temperature, speciation effects and the role of bilayer chain ordering on partitioning of dexamethasone and its 21-phosphate. Pharm Res 30 (12) : 3154-3169.
34. Ceh B, Lasic DD. 1995. A rigorous theory of remote loading of drugs into liposomes. Langmuir 11: 3356-3368.
35. Ceh B, Lasic DD. 1997. A rigorous theory of remote loading of drugs into liposomes: Transmembrane potential and induced pHgradient loading and leakage of liposomes. J Colloid Interf Sci 185 (1) : 9-18.
36. Modi S, Anderson BD. 2013. Determination of drug release kinetics from nanoparticles: Overcoming pitfalls of the dynamic dialysis method. Mol Pharm 10 (8) : 3076-3089.
37. Shibata H, Yomota C, Okuda H. 2013. Simultaneous determination of polyethylene glycol-conjugated liposome components by using reversed-phase high-performance liquid chromatography with UV and evaporative light scattering detection. AAPS PharmSciTech 14 (2) : 811-817.
38. Xiang T-X, Chen X, Anderson BD. 1992. Transport methods for probing the barrier domain of lipid bilayer membranes. Biophys J 63: 78-88.
39. Chaires JB, Dattagupta N, Crothers DM. 1982. Self-Association of daunomycin. Biochemistry 21 (17) : 3927-3932.
40. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ, Cullis PR. 1993. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1149 (2) : 329-338.
41. Xiang T-X, Anderson BD. 1997. Permeability of acetic acid across gel and liquid-crystalline lipid bilayers conforms to free-surface-Area theory. Biophys J 72 (1) : 223-237.
42. Xiang T-X, Anderson BD. 1998. Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape. Biophys J 75: 2658-2671.
43. Ichimori H, Hata T, Matsuki H, Kaneshina S. 1999. Effect of unsaturated acyl chains on the thermotropic and barotropic phase transitions of phospholipid bilayer membranes. Chem Phys Lipids 100: 151-164.
44. Clerc S, Barenholz Y. 1998. A quantitative model for using acridine orange as a transmembrane pH gradient probe. Anal Biochem 259 (1) : 104-111.
45. Haran G, Cohen R, Bar LK, Barenholz Y. 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151 (2) : 201-215.
46. Zucker D, Marcus D, Barenholz Y, Goldblum A. 2009. Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties. J Control Release 139 (1) : 73-80.
47. Cern A, Golbraikh A, Sedykh A, Tropsha A, Barenholz Y, Goldblum A. 2012. Quantitative structure-property relationship modeling of remote liposome loading of drugs. J Control Release 160 (2) : 147-157.
48. Barenholz Y. 2007. Amphipathic weak base loading into preformed liposomes having a transmembrane ammonium ion gradient: From the bench to approved Doxil. Liposome Technology (3rd Edition). Boca Raon, FL: CRC Press, Vol. 2, pp. 1-25.
49. Mayer LD, Bally MB, Cullis PR. 1986. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857 (1) : 123-126.
50. Mayer LD, Cullis PR, Bally MB. 1994. The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin. J Liposome Res 4: 529-553.
51. McLennan IJ, Lenkinski RE, Yanuka Y. 1985. A nuclear magnetic resonance study of the self-Association of adriamycin and daunomycin in aqueous solution. Can J Chem 63: 1233-1237.
52. Menozzi M, Valentini L, Vannini E, Arcamone F. 1984. Selfassociation of doxorubicin and related compounds in aqueous solution. J Pharm Sci 73 (6) : 766-770.
53. Anand R, Ottani S, Manoli F, Manet I, Monti S. 2012. A closeup on doxorubicin binding to c-cyclodextrin: An elucidating spectroscopic, photophysical and conformational study. RSC Adv 2: 2346-2357.
54. Angeloni L, Smulevich G, Marzocchi MP. 1982. Absorption, fluorescence and resonance Raman spectra of adriamycin and its complex with DNA. Spectrochim Acta 38A: 213-217.
55. Changenet-Barret P, Gustavsson T, Markovitsi D, Manet I, Monti S. 2013. Unravelling molecular mechanisms in the fluorescence spectra of doxorubicin in aqueous solution by femtosecond fluorescence spectroscopy. Phys Chem Chem Phys 15 (8) : 2937-2944.
56. Eksborg S. 1978. Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: Self-Association in aqueous solution. J Pharm Sci 67 (6) : 782-785.
57. Evstigneev MP, Khomich VV, Davies DB. 2006. Complexation of anthracycline drugs with DNA in the presence of caffeine. Eur Biophys J 36 (1) : 1-11.
58. Fülöp Z, Gref R, Loftsson T. 2013. A permeation method for detection of self-Aggregation of doxorubicin in aqueous environment. Int J Pharm 454: 559-561.
59. Agrawal P, Barthwal SK, Barthwal R. 2009. Studies on selfaggregation of anthracycline drugs by restrained molecular dynamics approach using nuclear magnetic resonance spectroscopy supported by absorption, fluorescence, diffusion ordered spectroscopy and mass spectrometry. Eur J Med Chem 44 (4) : 1437-1451.
60. Xiang T-X, Anderson BD. 1993. Diffusion of ionizable solutes across planar lipid bilayer membranes: Boundary layer pH gradients and the effects of buffers. Pharm Res 10: 1654-1661.
61. Dalmark M. 1981. Characteristics of doxorubicin transport in human red blood cells. Scand J Clin Lab Invest 41 (7) : 633-639.
62. Dalmark M, Storm HH. 1981. A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells. J Gen Physiol 78 (4) : 349-364.
63. Razzano G, Rizzo V, Vigevani A. 1990. Determination of phenolic ionization constants of anthracyclines with modified substitution pattern of anthraquinone chromophore. Farmaco 45 (2) : 215-222.
64. Righette PG, Menozzi M, Gainazzi E, Valentini L. 1979. Protolytic equilibria of doxorubicin as determined by isoelectric focusing and electrophoretic titration curves. FEBS Lett 101: 51-55.
65. Sturgeon RJ, Schulman SG. 1977. Electronic absorption spectra and protolytic equilibria of doxorubicin: Direct spectrophotometric determination of microconstants. J Pharm Sci 66 (7) : 958-961.
66. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. 1997. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331 (2) : 187-211.
67. Abraham SA, Edwards K, Karlsson G, MacIntosh S, Mayer LD, McKenzie C, Bally MB. 2002. Formation of transition metaldoxorubicin complexes inside liposomes. Biochim Biophys Acta 1565 (1) : 41-54.
68. Lasic DD, Ceh B, Stuart MC, Guo L, Frederik PM, Barenholz Y. 1995. Transmembrane gradient driven phase transitions within vesicles: Lessons for drug delivery. Biochim Biophys Acta 1239 (2) : 145-156.
69. Lasic DD. 1996. Doxorubicin in sterically stabilized liposomes. Nature 380 (6574) : 561-562.
70. Li X, Cabral-Lilly D, Janoff AS, Perkins WR. 2000. Complexation of internalized doxorubicin into fiber bundles affects its release rate from liposomes. J Liposome Res 10: 15-27.
71. Gabizon AA, Barenholz Y. 2005. Method for drug loading in liposomes. WO/2005/046643.